Molecular Formula | C21H18N4O4S |
Molar Mass | 422.46 |
Density | 1.38±0.1 g/cm3(Predicted) |
Melting Point | >193°C (dec.) |
Solubility | Chloroform (Slightly), DMSO (Slightly) |
Appearance | Solid |
Color | Grey to Brown |
pKa | 6.84±0.40(Predicted) |
Storage Condition | 2-8°C |
In vitro study | HS-173 showed potent anti-proliferative effects in T47D,SK-BR3, and MCF7 cells with IC50 of 0.6,1.5, and 7.8 μm, respectively. HS-173 completely inhibited the PI3K pathway in cancer cell lines (Hep3B and SkBr3). In addition, in in vitro assays, HS-173 induced apoptosis and blocked VEGF-induced angiogenesis by affecting cell cycle distribution and activating caspases. Sorafenib and HS-173 combination therapy has a synergistic anti-cancer effect on pancreatic cancer cells. |
In vivo study | HS-173 reduce blood vessel formation in mice. HS-173 significantly attenuates the development of liver fibrosis in vivo by blocking PI3K/Akt signaling. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.367 ml | 11.835 ml | 23.671 ml |
5 mM | 0.473 ml | 2.367 ml | 4.734 ml |
10 mM | 0.237 ml | 1.184 ml | 2.367 ml |
5 mM | 0.047 ml | 0.237 ml | 0.473 ml |